Skip to main content
Barry Zingman, MD, Infectious Disease, Bronx, NY

BarrySZingmanMD

Infectious Disease • Bronx, NY

HIV/AIDS Medicine

Professor, Medicine, Infectious Diseases, Albert Einstein College of Medicine

Join to view full profile

Dr. Zingman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Zingman's full profile

Already have an account?

  • Office

    111 E 210th St
    AIDS Center
    Bronx, NY 10467
    Phone+1 718-920-2647
    Fax+1 718-405-0610

Education & Training

  • Boston University Medical Center
    Boston University Medical CenterFellowship, Infectious Disease, 1988 - 1991
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1985 - 1988
  • New York University School of Medicine
    New York University School of MedicineClass of 1985

Certifications & Licensure

  • null
    null, NY 1991 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Remdesivir for the Treatment of Covid-19 — Final Report  
    Aneesh K Mehta, Barry S Zingman, Andre C Kalil, Helen Y Chu, Robert W Finberg, Kerry Dierberg, Victor Tapson, Lanny Hsieh, Thomas F Patterson, Daniel A Sweeney, Willia..., The New England Journal of Medicine

Press Mentions

  • Montefiore AIDS Center Awarded $1 Million to Curb Disproportionate Impact of HIV on Women of Color in the Bronx
    Montefiore AIDS Center Awarded $1 Million to Curb Disproportionate Impact of HIV on Women of Color in the BronxOctober 8th, 2024
  • Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-Risk COVID-19 Outpatient Study
    Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-Risk COVID-19 Outpatient StudyMay 9th, 2022
  • Montefiore/Einstein Lead Drug Trial on COVID-19 Antiviral Drug, Merck, Approved in the UK
    Montefiore/Einstein Lead Drug Trial on COVID-19 Antiviral Drug, Merck, Approved in the UKNovember 8th, 2021
  • Join now to see all

Professional Memberships

Dr. Barry Zingman, Dr. Barry Zingman, MD, Dr. B Zingman, Dr. Barry S Zingman